Longeveron
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Orphan and Rare Disease
Longeveron is a clinical-stage company developing Laromestrocel, an allogenic "off-the-shelf" bone marrow-derived mesenchymal stem cell therapy for rare pediatric diseases and chronic aging-related conditions.
Clinical Data & Pipeline Highlights
Hypoplastic Left Heart Syndrome (HLHS): Lead pediatric program is in a Phase 2b head-to-head trial versus standard of care. Data readout expected in August of 2026.
Phase 1 data showed 100% transplant-free survival at 5 years post treatment.
Designations: Orphan & Rare Pediatric-- Eligible for a Priority Review Voucher upon BLA approval
Alzheimer’s Disease:
Results: Phase 2a (CLEAR MIND) data demonstrated reductions cognitive decline and slowed hippocampal atrophy.
Designations: RMAT and Fast Track designations from the FDA.
Aging-Related Frailty:
Results: Demonstrated statistically significant, dose-dependent improvement in physical function and the 6-minute walk test at 9 months in a Phase 2 randomized, placebo-controlled trial.
Company HQ City:
Miami
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
2014
Lead Product in Development:
Lomecel-B (laromestrocel)
CEO
Steve Willard, CEO
Josh Hare, Co-founder, Chief Scientific Officer and Chairman of the Board
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
1 (with multiple indications/potential partners)
Exchange
Nasdaq
Ticker
LGVN
When you expect your next catalyst update?
August 2026
What is your next catalyst (value inflection) update?
Phase 2b study read out for HLHS
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}